메뉴 건너뛰기
The Lancet Oncology
Volumn 12, Issue 7, 2011, Pages 610-611
Adjuvant bisphosphonates for early-stage breast cancer
Author keywords

[No Author keywords available]
Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; TAXANE DERIVATIVE; ZOLEDRONIC ACID;
EID: 79959558701     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70151-6     Document Type: Letter
Times cited : (3)
References (7)
  • 1
    • 33947524592 scopus 로고    scopus 로고
    • Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
    • Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
    • (2007) J Clin Oncol , vol.25 , pp. 829-836
    • Brufsky, A.1    Harker, W.G.2    Beck, J.T.3
  • 2
    • 0036682211 scopus 로고    scopus 로고
    • Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
    • Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224.
    • (2002) J Clin Oncol , vol.20 , pp. 3219-3224
    • Powles, T.1    Paterson, S.2    Kanis, J.A.3
  • 3
    • 0032491037 scopus 로고    scopus 로고
    • Reduction in new metastases in breast cancer with adjuvant clodronate treatment
    • Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
    • (1998) N Engl J Med , vol.339 , pp. 357-363
    • Diel, I.J.1    Solomayer, E.F.2    Costa, S.D.3
  • 4
    • 45749089797 scopus 로고    scopus 로고
    • Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole
    • Z-FAST and ZO-FAST Study Groups
    • Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13:503-514. Z-FAST and ZO-FAST Study Groups.
    • (2008) Oncologist , vol.13 , pp. 503-514
    • Brufsky, A.1    Bundred, N.2    Coleman, R.3
  • 5
    • 79959565208 scopus 로고    scopus 로고
    • Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
    • on behalf of the Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
    • Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12:631-641. on behalf of the Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
    • (2011) Lancet Oncol , vol.12 , pp. 631-641
    • Gnant, M.1    Mlineritsch, B.2    Stoeger, H.3
  • 6
    • 79953803585 scopus 로고    scopus 로고
    • Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04)
    • abstr S4-5.
    • Coleman RE, Thorpe HC, Cameron D, et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04). Breast Cancer Treat Res 2010, 72. abstr S4-5.
    • (2010) Breast Cancer Treat Res , vol.72
    • Coleman, R.E.1    Thorpe, H.C.2    Cameron, D.3
  • 7
    • 46849110780 scopus 로고    scopus 로고
    • Practical guidance for the management of aromatase inhibitor-associated bone loss
    • Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416.
    • (2008) Ann Oncol , vol.19 , pp. 1407-1416
    • Hadji, P.1    Body, J.J.2    Aapro, M.S.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.